Expert system for infusion pump therapy

Information

  • Patent Grant
  • 9474856
  • Patent Number
    9,474,856
  • Date Filed
    Monday, April 13, 2015
    9 years ago
  • Date Issued
    Tuesday, October 25, 2016
    8 years ago
Abstract
An apparatus comprising a controller. The controller includes an input/output (I/O) module and a rule module. The I/O module is configured to present a question for a patient when communicatively coupled to a user interface and receive patient information in response to the question via the user interface. The rule module is configured to apply a rule to the patient information and generate a suggested insulin pump setting from application of the rule. Other devices, systems, and methods are disclosed.
Description
TECHNICAL FIELD

The field generally relates to patient insulin management devices and, in particular, but not by way of limitation, to systems, devices and methods for managing insulin therapy.


BACKGROUND

People who suffer from diabetes require insulin to keep their blood glucose level as close as possible to normal levels. It is essential for people with diabetes to manage their blood glucose level to within a normal range. Complications from diabetes can include heart disease (cardiovascular disease), blindness (retinopathy), nerve damage (neuropathy), and kidney damage (nephropathy). Insulin is a hormone that reduces the level of blood glucose in the body. Normally, insulin is produced by beta cells in the pancreas. In non-diabetic people, the beta cells release insulin to satisfy two types of insulin needs. The first type is a low-level of background insulin that is released throughout the day. The second type is a quick release of a higher-level of insulin in response to eating. Insulin therapy replaces or supplements insulin produced by the pancreas.


Conventional insulin therapy typically involves one or two injections a day. The low number of injections has the disadvantage of allowing larger variations in a person's insulin levels. Some people with diabetes manage their blood glucose level with multiple daily injections (MDI). MDI may involve more than three injections a day and four or more blood glucose tests a day. MDI offers better control than conventional therapy. However, insulin injections are inconvenient and require a diabetic person to track the insulin doses, the amount of carbohydrates eaten, and their blood glucose levels among other information critical to control.


It is important for a diabetic person to be treated with the proper amount of insulin. As discussed previously, high blood sugar can lead to serious complications. Conversely, a person with low blood sugar can develop hypoglycemia. Ideally, insulin therapy mimics the way the body works. An insulin pump is one way to mimic the body's insulin production. An insulin pump can provide a background or basal infusion of insulin throughout the day and provide a quick release or bolus of insulin when carbohydrates are eaten. If a person develops high blood sugar, a correction bolus can be delivered by the pump to correct it. While insulin pumps improve convenience and flexibility for a diabetic person, they can be sophisticated devices. Some insulin pumps can be difficult to program. Proper use of an insulin pump requires a user to go through a learning curve to properly treat their diabetes using the insulin pump.


SUMMARY

This document discusses, among other things, devices and methods for managing insulin therapy. A device example includes a controller. The controller includes an input/output (I/O) module and a rule module. The I/O module is configured to present a question for a patient when communicatively coupled to a user interface and receive patient information in response to the question via the user interface. The rule module is configured to apply a rule to the patient information and generate a suggested insulin pump setting from application of the rule.


A method example includes presenting a question for a diabetic patient using a device, receiving patient information into the device in response to the question, applying a rule to the patient information, and generating a suggested insulin pump setting from application of the rule.


This summary is intended to provide an overview of the subject matter of the present patent application. It is not intended to provide an exclusive or exhaustive explanation of the invention. The detailed description is included to provide further information about the subject matter of the present patent application.





BRIEF DESCRIPTION OF THE DRAWINGS


FIGS. 1A and 1B illustrate portions of a device that includes an insulin pump.



FIG. 2 is a block diagram of an example of portions of a device to provide assistance in maintaining and adjusting a patient's insulin pump therapy.



FIG. 3 shows a flow diagram of a method to provide assistance in maintaining and adjusting a patient's insulin pump therapy.



FIG. 4 is a block diagram of another example of portions of a device to provide assistance in maintaining and adjusting a patient's insulin pump therapy.



FIG. 5 is a diagram of yet another example of portions of a device to provide assistance in maintaining and adjusting a patient's insulin pump therapy.



FIG. 6 is a block diagram of a further example of portions of a device to provide assistance in maintaining and adjusting a patient's insulin pump therapy.





DETAILED DESCRIPTION

The following detailed description includes references to the accompanying drawings, which form a part of the detailed description. The drawings show, by way of illustration, specific embodiments in which the invention may be practiced. These embodiments, which are also referred to herein as “examples,” are described in enough detail to enable those skilled in the art to practice the invention. The embodiments may be combined, other embodiments may be utilized, or structural, logical and electrical changes may be made without departing from the scope of the present invention. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope of the present invention is defined by the appended claims and their equivalents.


In this document, the terms “a” or “an” are used, as is common in patent documents, to include one or more than one. In this document, the term “or” is used to refer to a nonexclusive or, such that “A or B” includes “A but not B,” “B but not A,” and “A and B,” unless otherwise indicated. Furthermore, all publications, patents, and patent documents referred to in this document are incorporated by reference herein in their entirety, as though individually incorporated by reference. In the event of inconsistent usages between this document and those documents so incorporated by reference, the usage in the incorporated reference(s) should be considered supplementary to that of this document; for irreconcilable inconsistencies, the usage in this document controls.



FIGS. 1A and 1B illustrate portions of a device 100 that includes an insulin pump. The device 100 includes a cassette or cartridge of insulin. The cartridge is connectable to infusion tubing 140 connectable to a patient such as by a Luer lock 145 or infusion set 142. The device 100 includes a display 102 and a user interface that may include the display 102 and include one or more keys 104. Because proper use of an insulin pump requires a user to go through a learning curve to properly treat their diabetes using the pump, it is desirable for a pump to provide assistance to the user, whether the user is a diabetic patient, a caregiver, or a clinician. An expert system provides assistance or coaching to the user to effectively treat their diabetes using the insulin pump device.



FIG. 2 is a block diagram of an example of portions of a device 200 to provide assistance in maintaining and adjusting a patient's insulin pump therapy. The device 200 includes a controller 205. The controller 205 can be implemented using hardware circuits, firmware, software or any combination of hardware, firmware and software. Examples, include a microcontroller, a logical state machine, and a processor such as a microprocessor, application specific integrated circuit (ASIC), or other type of processor. The controller 205 is configured to perform or execute a function or functions. Such functions correspond to modules, which are software, hardware, firmware or any combination thereof. Multiple functions may be performed in one or more modules. In some examples, software or firmware is provided on a computer readable medium. The computer readable includes instructions therein, which when processed (such as by the controller 205 for example) results in a device performing the functions described herein. Examples of a computer readable medium include a compact disc (CD), memory stick, or remote storage accessible via a communication network such as the internet or a cell phone network.


The controller 205 includes an input-output (I/O) module 210. The I/O module 210 presents a question for a patient when the I/O module 210 is communicatively coupled to a user interface. The user interface may include one or more pushbuttons or a keypad. The user interface may include a display to visually present instructions and/or the question to the user. The user of the device 200 may be a clinician or a diabetic patient. The display may include a touch-screen. The user interface may include a speaker to present instructions and questions audibly. A speaker may be desirable when the user has difficulty in reading a display.


The I/O module 210 receives patient information in response to the question via the user interface. In some examples, the question and response is included in a series of questions and responses that are part of a patient interview by the device 200. A patient interview may cover a broad range of information. In some examples, the patient information may include patient health information such as a patient health status or whether the patient has any other health-related conditions. The health information also may include whether information concerning any drugs or medications the patient may be taking. Some drugs may cause a person to need more insulin, or the patient may be taking a drug to slow down the absorption of food.


The patient information may include patient lifestyle information. The lifestyle information may include whether a patient tends to eat high glycemic index foods, drinks alcohol, smokes, eats a bedtime snack, a health status of the patient, whether the patient is typically under stress, whether the patient tends to be active, and the amount time the patient spends exercising, for example. The patient information may include patient demographic information. The demographic information may include a patient's weight, age, and gender for example.


In some examples, the patient information may be stored in a memory 220 communicatively coupled to the controller 205. The information may be stored in response to the questions or may be pre-stored in the device 200. The controller 205 includes a rule module 215. The rule module 215 applies a rule to the patient information and generates a suggested insulin pump setting from application of the rule. In some embodiments, the rule includes a decision tree. A decision tree may be implemented with a series of IF-Then logic statements. The controller 205 traverses the decision tree using the patient information. In some embodiments, the rule module 215 may include a look-up table stored in the memory 220. The look-up table may have entries that include one or more insulin pump settings. The table may include multiple dimensions to take into account multiple factors, responses, or other information.


An example of an insulin pump setting is a basal rate. Basal rate refers to a type of twenty-four hour background infusion of insulin by an insulin pump that mimics the continuous background release of insulin from a normal pancreas. It is the rate of insulin delivery the patient normally needs independent of the consumption of meals. The basal rate is typically specified in insulin units per hour (u/hr). The patient information may include a total daily dose (TDD) of insulin, or the rule module may determine a TDD from patient information including the type of diabetes of the patient and the patient's weight, age, and level of fitness. The rule included in the rule module 215 may determine that the amount of daily basal insulin according to a percentage of TDD, such as 40%, 50%, or 60% for example. The percentage applied by the rule may be customized according to the preferences of a clinician. The TDD is then divided by 24 to obtain an average hourly basal rate. For example, if a patient's TDD is determined to be 40 units of insulin, and 50% of the TDD is used for basal delivery, the rule module 215 determines that the average basal rate is 20 units/24 hours or 0.83 u/hr.


Many insulin pump users may use three or more different basal rates during the course of a day. Basal rates can be adjusted to change delivery every few minutes (e.g., 20-30 minutes) by increments as small as 0.05 u/hr to better track changes in demand, such as from an increase typically needed before dawn or a decrease needed during long active periods. The device 200 provides assistance in determining one or more basal rates for the patient. For example, the rule may be a look-up table that includes one or more basal rates indexed by an activity level of the patient. The rule determines a lower basal rate during an increased activity level of the patient. In another example, the rule may increase a basal rate during times when the patient takes a drug that causes the patient to need more insulin. In yet another example, the rule may decrease a basal rate or a segment of a basal rate pattern if the patient is taking a drug to delay the digestion of food.


Another example of an insulin pump setting is a correction factor. A correction factor refers to the amount in drop in blood sugar, or blood glucose, for one unit of insulin. It is measured in milligrams per deciliter (mg/dl) per unit in the U.S. and in millimoles (mmol) per unit in other countries. An insulin pump may use the correction factor to automatically determine a bolus amount required for a high reading or a reduction in a meal bolus for a below-target reading. The insulin pump may also use the correction factor to calculate the amount of carbohydrates a patient should eat to bring low blood sugar up to a target blood sugar level. An appropriate correction factor brings a high blood glucose reading down using an automatically determined correction bolus without a risk of going low.


The rule module 215 may include a rule such as the “1800 rule” in setting the correction factor. For example, if a person's TDD is 40 units of insulin, the correction factor would be 1800/40, or 45 mg/dl per unit. (The 1800 rule corresponds to a “100 rule” if mmol are used.) The rule module 215 may also take into account factors such as a person's age, weight, and activity level when setting the correction factor. Other rules include the 1700 rule (94 rule if mmol) and the 1500 rule (83 rule if mmol). For example, under the 1700 rule the correction factor would be 1700/40 or 42.5 mg/dl. A clinician may prefer one rule over another based on experience including rules that are not based on TDD. The rule to determine the correction factor may be customized according to the preferences of the clinician.


Another example of an insulin pump setting is a carbohydrate ratio. A carbohydrate ratio refers to the amount of carbohydrates covered by a unit of insulin. It is sometimes referred to as a carbohydrate factor, or carb factor, and is typically specified as grams of carbohydrates per unit of insulin. An insulin pump device may use the carbohydrate ratio to automatically determine a carbohydrate insulin bolus amount required to match a number of carbohydrates ingested by the patient, or at least to keep post-meal blood glucose within a range that is healthy for a patient. For example, the patient may plan to eat seventy grams of carbohydrates. If the carbohydrate ratio is ten grams of carbohydrates per unit of insulin, the insulin pump may determine that seven units of insulin are required to cover the carbohydrates.


The rule module 215 may include a formula such as the “500 rule” in setting the carbohydrate ratio. For example, if a person's TDD is 40 units of insulin, the carbohydrate ratio would be 500/40 or about 13 grams per unit of insulin. The rule module 215 may also take into account factors such as a person's age, weight, and activity level when setting the carbohydrate ratio. Other formulas include the 550 rule and the 600 rule. For example, under the 600 rule the carbohydrate ratio would be 600/40 or 15 grams per unit of insulin. As discussed above, the larger the carbohydrate ratio, the smaller a carbohydrate bolus becomes. Because a clinician may prefer one rule over another based on experience; including rules that are not based on TDD, the rule to determine the correction factor may be customized according to the preferences of the clinician.


According to some examples, the memory 220 may store parameters associated with an insulin pump initial setup. The rule module 215 applies a rule to match the insulin pump parameters to at least one of patient health information, patient lifestyle information, and patient demographic information to generate a suggested insulin pump initial setup. The rule module 215 may apply the rule to the patient information to determine at least one of an initial correction factor, an initial carbohydrate ratio, and one or more initial basal rate patterns or profiles. For example, as part of the device interview a patient may enter those periods when the patient regularly exercises into the device 200. The rule may generate different basal rates before, during, or after the exercise periods. In another example, the patient enter the fact that she is pregnant or trying to get pregnant into the device 200. The rule may suggest more aggressive correction bolus targets. In a further example, based on the demographic data the rule may determine different insulin pump initial setups for children, teens, adult females, adult males, and seniors. The demographic information would initially setup parameters including basal rates, carbohydrate bolus limits, insulin pump feature lockouts and enables.



FIG. 3 shows a flow diagram of a method to provide assistance in maintaining and adjusting a patient's insulin pump therapy. At block 305, a question is presented for a diabetic patient using a device. At block 310, patient information is received into the device in response to the question. At block 315, a rule is applied to the patient information. At block 320, a suggested insulin pump setting is generated from application of the rule.



FIG. 4 is a block diagram of another example of portions of a device 400 to provide assistance in maintaining and adjusting a patient's insulin pump therapy. The device 400 includes an insulin pump 425 or pump mechanism to deliver insulin to a patient, such as a positive displacement pump for example. The device 400 also includes a controller 405 communicatively coupled to a memory 420. The controller 405 includes an I/O module 410 and a rule module 415. The memory 420 may store parameters associated with insulin pump therapy. The rule module 415 applies a rule to generate a suggested insulin pump initial setup.


The device 400 includes a user interface 430 communicatively coupled to the I/O module 410. In some examples, the user interface 430 includes a display and the I/O module 410 presents one or more suggested insulin pump settings to the user via the user interface 430. The I/O module additionally presents a request to the user for confirmation of the insulin pump setting. After a request is received, the setting or settings are adopted or activated by the device 400, such as by moving the settings from the memory 420 to operating registers for example.



FIG. 5 is a diagram of an example of a device 500 to provide assistance in maintaining and adjusting a patient's insulin pump therapy. The device 500 includes a computing device 550. Examples of a computing device 550 include among other things a personal computer (PC), laptop computer, and personal data assistant (PDA). The computing device 550 includes a controller 505. The controller 505 includes an I/O module 510 and a rule module 515. The computing device 550 also includes a user interface 555 that includes a display and may include at least one of a keyboard or keypad and a computer mouse. The computing device 550 further includes a communication port 545 communicatively coupled to the I/O module 510. The device 500 communicates information with an insulin pump 570 via the communication port 545. In some examples, the communication port 545 is a wireless port and the device 500 communicates with the insulin pump 570 using wireless signals, such as a radio frequency (RF) port or infrared (IR) port for example. In some examples, the communication port 545 is a wired port (e.g., a serial port) and the device 500 communicates with the insulin pump using a removable communication cable.


The rule module 515 applies a rule to generate at least one insulin pump setting. The I/O module 510 presents the setting to a user as a suggested insulin pump setting via the user interface 555. The I/O module 510 also presents a request for confirmation of the insulin pump setting. When the I/O module 510 receives a confirmation, such as through the user interface 555 for example, the I/O module 510 communicates the insulin pump setting to the insulin pump 570 via the communication port 545.


As set forth previously, a rule may be customized. In some examples, the controller 505 includes a rule development module 560 to develop a rule via edits received via the I/O module 510. The rule development module 560 is a rule editor that edits existing rules in addition to generating new rules. In some examples, the rule development module 560 displays a representation 580 of the rule when the I/O module 510 is communicatively coupled to the user interface 555. The rule development module 560 converts a manipulation of the displayed representation 580 via the user interface into the edit to the rule.


The rule development module 560 provides doctors or clinical experts the ability to develop and generate a new rule (or rule set) or to modify rules via the user interface 555. The computing device 550 includes software that provides a flexible framework to create or modify rules such as by updating a graphical decision tree or a look-up table for example. The software may be included in a computer readable medium, such as a compact disc (CD) for example, or the software may be downloaded to the computing device 550 from remote storage, such as from a server for example. The computing device 550 uses the communication port 545 to communicate the rule or rule set to the insulin pump 570.


Once a rule is developed, the doctor or clinical expert could publish or otherwise share a rule or set of rules. In some embodiments, rule sets can be stored in remote storage, such as a server for example. The computing device 550 may be connected to a communication network, such as the internet or a cell phone network for example. A doctor or clinical expert may download a rule or rule set from the remote storage and either download the rule set directly from the computing device 550 into the insulin pump device 570 or modify the rule or rule set before downloading the modified rule or rule set to the insulin pump device 570.


Returning to FIG. 4, the controller 405 may include a rule development module. The user interface 430 receives edits to a rule or rule set. The edits are entered into the device 400 manually by the user via the user interface 430. For example, the user may step through the rule with the aid of a display included in the user interface 430. The user may then alter the rule with a keypad included in the user interface 430. For example, the user may enter a new look up table entry using the key pad, or add another branch to a decision tree or edit a branch of the decision tree. In certain examples, an entire new rule or rule set is entered manually into the device 400 via the user interface 430.


In some examples, the device 400 of FIG. 4 or the insulin pump device 570 of FIG. 5 stores data to track effectiveness of a new rule or modified rule. For example, the insulin pump device 570 may track the number of times the blood glucose level of the patient returned to a target blood glucose level or to within a target range of levels after application of the rule. The effectiveness may be displayed as a percentage or as X successes out of Y applications on either a display of the insulin pump device 570 or uploaded and displayed on a separate device, such as the computing device 550 in FIG. 5 for example.


Returning to the device of FIG. 2, in some examples, the rule module 215 assigns weights to corresponding table entries in a rule. For example, a certain type of exercise (e.g. higher intensity) may be weighted higher when determining whether to suggest a different basal rate for the patient during the exercise (versus suggesting a food to eat before exercise of lower intensity). In some examples, the rule module 215 uses one or more fuzzy logic rules to determine the question for display and any recommended action. The fuzzy logic rules may be used to blend any weighted questions, responses, or actions. In some examples, the rule module 215 uses a rule involving application of artificial intelligence methods to determine the questions and the actions to be presented. In some examples, the weighting used by the rule is customizable.


In some examples, the memory 220 stores a database of food options in association with a known amount of nutrient content. The rule module 215 uses the patient health, lifestyle, and demographic information set forth above and generates a suggested database of food options. For example, if the patient lifestyle information indicates that the patient tends to eat high glycemic index foods, or the patient health information indicates that the patient is pregnant, the suggested data base may include mostly low glycemic foods. If the controller 205 is included in a computing device 550 of FIG. 5 or other type of device, that device communicates the suggested database to the insulin pump device 570 where it is stored. If the controller 205 is included in an insulin pump device as in FIG. 4, the controller 405 only displays the suggested portion of the database to a user.


Without an expert system, a pump user may go through several iterations of trial and error in finding appropriate insulin pump settings. In some examples, the device 200 uses blood glucose information as feedback to better tune insulin pump settings. The rule module 215 applies the rule to blood glucose information, such as blood glucose data taken using a blood glucose monitor (GM), to determine one or more insulin pump settings.


The I/O module 210 may present an action for the user to take. In some examples, the action presented may be a prompt for the user to enter blood glucose data into the device, download blood glucose data into the device, or to begin a blood glucose measurement. For example, the action presented may be a prompt to measure blood glucose level from a finger stick and to enter the data into the I/O module 210 through a user interface. In some examples, the device 200 includes a communication port communicatively coupled to the controller 205. The I/O module 210 receives the blood glucose data via the communication port from a second separate device that includes a glucose monitor. In some examples, the communication port includes a wireless communication port. A separate device may obtain the blood glucose data during a test executed using an insulin pump. In some examples, the device 200 includes an insulin pump communicatively coupled to the controller 205.


In some examples, the device 200 includes a GM. FIG. 6 is a diagram of another example of a device 600 to provide assistance in maintaining and adjusting a patient's insulin pump therapy. The device 600 includes a controller 605 communicatively coupled to a memory 620. The controller 605 includes an I/O module 610 and a rule module 615. The device also includes a GM 680 communicatively coupled to the controller 605. In some examples, the device 600 also includes an insulin pump communicatively coupled to the controller 605.


If the GM 680 is a continuous GM, no action is needed from the user to obtain blood glucose data. A continuous GM includes a blood glucose sensor to produce a blood glucose signal representative of a blood glucose level of the patient. The blood glucose sensor may sense blood glucose concentration from blood or interstitial fluid. The blood glucose sensor circuit may include a sensor interface circuit to sample the blood glucose signal and may provide additional signal processing such as filtering or amplification for example. The blood glucose sensor circuit may provide sampled blood glucose data to the I/O module 610. A description of a blood glucose sensor circuit can be found in Steil et al., U.S. Pat. No. 6,558,351, filed Jun. 1, 2000.


Returning to FIG. 2, the action presented by the I/O module 210 may include prompting the user to begin a test or a series of tests in which blood glucose data is monitored and received into the device 200 via the I/O module 210. A test may be executed using an insulin pump. The rule module 215 applies the rule to at least one of the blood glucose data and the patient information to determine an insulin pump setting. In some examples, the rule module 215 generates an insulin pump setting that includes a target blood glucose level for the patient. The target blood glucose level may be a range of blood glucose levels.


Because a patient's basal insulin needs may change over time, such as with weight change or with a change in fitness level, basal rate testing may be performed periodically to ensure that an appropriate basal rate is being delivered by an insulin pump. Based on blood glucose data (e.g., the blood glucose level of the patient is not at the target blood glucose level), the rule module 215 may determine from the rule that a basal rate test should be run (by either the insulin pump included with the device 200 or a separate device). The I/O module 210 may present (such as by display) a suggestion to the user to execute a basal rate test. As a result of the basal rate test, the rule module 215 generates one or more basal rate patterns or profiles. The I/O module 210 may display a recommendation to change a programmable basal rate pattern of the insulin pump. Descriptions of devices and methods that perform a basal rate test are found in Blomquist et al., “Basal Rate Testing Using Frequent Blood Glucose Input,” U.S. patent application Ser. No. 11/685,617, filed Mar. 13, 2007, which is incorporated herein by reference.


If a carbohydrate ratio is too small, the insulin pump may determine a carbohydrate bolus that is too large for the carbohydrates consumed. This may cause a low blood glucose level within a few hours of the carbohydrate bolus (e.g., the blood glucose level drops below 70 mg/dl). If a carbohydrate bolus is too large, the insulin pump may determine a carbohydrate bolus that is too small for the carbohydrates consumed. This may cause a high blood glucose level within a few hours of a carbohydrate bolus.


Based on the blood glucose data, the rule module 215 may determine that a recommendation to run a carbohydrate ratio test should be presented. As a result of the carbohydrate ratio test, the rule module 215 may generate a new carbohydrate ratio. The I/O module 210 may present a recommendation to change the carbohydrate ratio programmed in the insulin pump. In some examples, the rule module 215 may generate a carbohydrate insulin bolus pattern or profile to be delivered by the insulin pump. For example, the I/O module 210 may display a recommended carbohydrate bolus pattern that includes an extended carbohydrate bolus or a combination bolus. Descriptions of devices and methods that perform a carbohydrate ratio test are found in Blomquist, “Carbohydrate Ratio Testing Using Frequent Blood Glucose Input,” U.S. patent application Ser. No. 11/679,712, filed Feb. 27, 2007, which is incorporated herein by reference.


It is important for an insulin pump to use an effective correction factor. If a correction factor for a pump is set too high, the blood glucose may not actually be dropping as much as estimated and could lead to high blood glucose levels. If the correction factor is set too low, a correction bolus may provide too much insulin and result in a low blood glucose level.


Based on the blood glucose data, the rule module 215 may apply the rule to the blood glucose data and present a recommendation that the user initiate a correction factor test. As a result of the correction factor test, the rule module 215 may generate a new a correction factor. The I/O module 210 may present a recommendation to change the correction factor programmed in the insulin pump. In some examples, the rule module 215 may generate an insulin correction bolus pattern or profile. For example, the I/O module 210 may display a recommended correction bolus such as a pattern including different correction factors for different times of the day for example. Descriptions of devices and methods that perform a carbohydrate ratio test are found in Blomquist et al., “Correction Factor Testing Using Frequent Blood Glucose Input,” U.S. patent application Ser. No. 11/626,653, filed Jan. 24, 2007, which is incorporated herein by reference. If the device 200 includes an insulin pump, the controller 205 may executes one of the tests described.


The examples set forth above involved the device 200 recommending an action for the user to take based on the blood glucose data received into the device. In some examples, the rule module 215 may use the blood glucose data to first generate a question to be presented by the I/O module 210 before presenting an action. The rule module 215 generates the suggested insulin pump setting from application of the rule to the blood glucose data and patient information received in response to the question. For example, if the blood glucose data indicates blood glucose is low, the rule may include a look up table having a question as to whether the patient had a high activity level. If the device 200 receives a response through a user interface that the activity level was high, the look up table may include a recommended action corresponding to a table entry for low blood glucose and high activity. The table entry may include a recommended action that the patient eat before the activity or lower a programmable basal rate of insulin before, during, or after the activity.


In some examples, the controller 205 determines a rate of change of a blood glucose level of the patient from the blood glucose data. As an illustrative example, the controller 205 may determine that the blood glucose concentration level is increasing or decreasing at a rate of 2 to 4 mg/di/min (milligrams per deciliter per minute). The rule module 215 may apply one or more rules to the rate of change of a blood glucose level to generate a suggested insulin pump setting. If the blood glucose level is high and increasing at a certain rate, the rule module 215 may apply the rule to generate an insulin correction bolus pattern.


The action presented by the I/O module 210 may be a test or tests that include a variety of steps. The tests may be included in the rule module 215 and are designed to obtain data or other information that is analyzed by the rule. The tests may occur over a series of days. For example, during the test the device 200 may instruct the insulin pump user to skip breakfast the first day, skip lunch the second day, and skip dinner the third day. The device 200 may display an action for the user that includes taking blood glucose measurements at specified times in the test, such as pre-meal, post-meal, and while fasting for example. The device 200 may ask the user to perform or not perform certain activities (e.g., exercise) during the testing. The device may present an action to the user to eat specific portions of food having specific nutritional content. As part of the test, the device 200 may ask the user to input patient information into the device 200 (e.g., through the user interface, or through a second separate device that communicates with the device 200 via a communication port). The patient information may include health information, stress level information, or other information pertinent to later test analysis.


After the testing, the device 200 presents one or more questions to the user. The questions and responses from the user are part of a post-test patient interview by the device 200. The information from the patient interview and the blood glucose data are then analyzed. The rule module 215 applies the rule to the responses during the interview, the blood glucose data obtained as part of the test, and any other test data. The rule module 215 generates changes to insulin therapy parameters. In some examples, the changes are presented to the user, and the user has the option of accepting the changes.


If the device 200 includes an insulin pump, the changes are adopted by the device 200. If the device is a computing device such as in FIG. 5, or a device that includes a GM that is separate from the insulin pump, the changes may be communicated to the insulin pump. According to some examples the functions can be accomplished using multiple devices. For example, a first device may guide the patient through the test or tests. This device may include an insulin pump such as the device 400 in FIG. 4. The patient interview and analysis may be done by a second device such as the device 500 in FIG. 5.


As set forth previously, a rule or set of rules may be customized, such as by a rule development module included in the controller 205 for example. In some examples, all or substantially all aspects of the rule are customizable, including the type of tests to run, the sequence of tests to run, the steps in the tests, and the criteria for making changes. An expert in the treatment of diabetes would customize the rules to suit their standard of practice.


According to some embodiments, the device 200 may present changes other than insulin pump therapy parameters. In some examples, the rule module 215 may generate a recommend change to a patient lifestyle, such as a recommendation to exercise more or to reduce smoking. The I/O module 210 presents the recommend changes to the lifestyle of the patient. In some examples, the rule module 215 may generate a recommend change to a patient diet, such as a recommendation to eat foods having a lower glycemic index or to consume less alcohol.


It is to be understood that the above description is intended to be illustrative, and not restrictive. For example, the above-described embodiments (and/or aspects thereof) may be used in combination with each other. Many other embodiments will be apparent to those of skill in the art upon reviewing the above description. The scope of the invention should, therefore, be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled. In the appended claims, the terms “including” and “in which” are used as the plain-English equivalents of the respective terms “comprising” and “wherein.” Also, in the following claims, the terms “including” and “comprising” are open-ended, that is, a system, device, article, or process that includes elements in addition to those listed after such a term in a claim are still deemed to fall within the scope of that claim. Moreover, in the following claims, the terms “first,” “second,” and “third,” etc. are used merely as labels, and are not intended to impose numerical requirements on their objects.


The Abstract of the Disclosure is provided to comply with 37 C.F.R. .sctn.1.72(b), requiring an abstract that will allow the reader to quickly ascertain the nature of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. In addition, in the foregoing Detailed Description, it can be seen that various features are grouped together in a single embodiment for the purpose of streamlining the disclosure. This method of disclosure is not to be interpreted as reflecting an intention that the claimed embodiments require more features than are expressly recited in each claim. Rather, as the following claims reflect, inventive subject matter lies in less than all features of a single disclosed embodiment. Thus the following claims are hereby incorporated into the Detailed Description, with each claim standing on its own.

Claims
  • 1. An apparatus, comprising: a user interface including a display;a controller communicatively coupled to the user interface and the display, the controller including: an input/output module configured to: present a series of questions to a patient on the display; andreceive patient information about the patient in response to the questions through the user interface; anda rule module configured to: apply a rule to the patient information;generate a suggested infusion pump setting according to the application of the rule to the patient information; andpresent the suggested infusion pump setting on the display; anda communications port communicatively coupled to the controller and configured to communicate the suggested infusion pump setting to a programmable infusion pump for use in a subsequently initiated infusion protocol with the programmable infusion pump.
  • 2. The apparatus of claim 1, wherein the communications port is a wireless port that wirelessly communicates the suggested infusion pump setting to the programmable infusion pump.
  • 3. The apparatus of claim 1, wherein the input/output module is further configured to receive, through the user interface, a confirmation of the suggested infusion pump setting and the communications port communicates the suggested infusion pump setting to the programmable infusion pump after the confirmation is received.
  • 4. The apparatus of claim 1, further comprising a memory storing the rule.
  • 5. The apparatus of claim 1, wherein the input/output module is further configured to access a remote device to obtain the rule.
  • 6. The apparatus of claim 1, wherein the controller is further configured to receive data relating to the effectiveness of the rule from the programmable infusion pump through the communications port.
  • 7. The apparatus of claim 1, wherein the input/output module is further configured to receive information relating to a glucose level of a patient and applying a rule to the patient information includes applying the rule to the glucose level information.
  • 8. The apparatus of claim 1, wherein the user interface, the controller, the display and the communications port define a computing device.
  • 9. The apparatus of claim 8, wherein the computing device is a handheld mobile device.
  • 10. The apparatus of claim 1, wherein the suggested infusion pump setting is suggested for initial setup of an infusion protocol on the programmable infusion pump.
  • 11. An apparatus comprising: a controller including: an input/output module configured to: present a series of questions to a patient on a display; andreceive patient information about the patient in response to the questions through a user interface; anda rule module configured to: apply a rule to the patient information; andgenerate a suggested infusion pump setting according to the application of the rule to the patient information; andpresent the suggested infusion pump setting on the display; anda communications port communicatively coupled to the controller and configured to communicate the suggested infusion pump setting to a programmable infusion pump for use in a subsequently initiated infusion protocol with the programmable infusion pump.
  • 12. The apparatus of claim 11, wherein the communications port is a wireless port that wirelessly communicates the suggested infusion pump setting to the programmable infusion pump.
  • 13. The apparatus of claim 11, wherein the input/output module is further configured to: present a request for confirmation of the suggested infusion pump setting on the display; andcommunicate the suggested infusion pump setting to the programmable infusion pump after receiving the confirmation.
  • 14. The apparatus of claim 11, wherein the controller is further configured to receive data relating to the effectiveness of the rule from the programmable infusion pump through the communications port.
  • 15. The apparatus of claim 11, wherein the input/output module is further configured to receive information relating to a glucose level of a patient and the rule module is further configured to apply the rule to the glucose level information.
  • 16. The apparatus of claim 11, wherein the controller and communications port are part of a computing device.
  • 17. The apparatus of claim 16, wherein the computing device is a handheld mobile device.
  • 18. The apparatus of claim 11, wherein the suggested infusion pump setting is suggested for initial setup of an infusion protocol on the programmable infusion pump.
  • 19. A method comprising: presenting a series of questions to a patient on a display of a computing device;receiving patient information about the patient in response to the questions through a user interface of the computing device;applying a rule to the patient information with an electronic controller of the computing device;generating a suggested infusion pump setting with the electronic controller according to the application of the rule to the patient information;presenting the suggested infusion pump setting on the display; andcommunicating, with a communications port of the computing device, the suggested infusion pump setting to a programmable infusion pump for use in a subsequently initiated infusion protocol with the programmable infusion pump.
  • 20. The method of claim 19, wherein communicating the suggested infusion pump setting to the programmable infusion pump includes wirelessly communicating the suggested infusion pump setting.
  • 21. The method of claim 19, further comprising receiving a confirmation of the suggested infusion pump setting and communicating the suggested infusion pump setting to the programmable infusion pump is done after the confirmation is received.
  • 22. The method of claim 19, further comprising receiving data relating to the effectiveness of the rule from the programmable infusion pump through the communications port.
  • 23. The method of claim 19, further comprising receiving information relating to a glucose level of a patient and applying a rule to the patient information includes applying the rule to the glucose level information.
  • 24. The method of claim 19, wherein the computing device is a handheld mobile device.
  • 25. The method of claim 19, wherein generating a suggested infusion pump setting generates the suggested infusion pump setting for initial setup of an infusion protocol on the programmable infusion pump.
RELATED APPLICATIONS

This application is a continuation of application Ser. No. 13/530,404 filed Jun. 22, 2012, which in turn is a continuation of application Ser. No. 12/774,991 filed May 6, 2010, now U.S. Pat. No. 8,219,222 issued Jul. 10, 2012, which in turn is a continuation application Ser. No. 11/753,420 filed May 24, 2007, now U.S. Pat. No. 7,751,907 issued Jul. 6, 2010, each of which is hereby fully incorporated herein by reference.

US Referenced Citations (373)
Number Name Date Kind
5000664 Lawless et al. Mar 1991 A
5181910 Scanlon Jan 1993 A
5219330 Bollish Jun 1993 A
5338157 Blomquist Aug 1994 A
5368562 Blomquist Nov 1994 A
5389078 Zalesky et al. Feb 1995 A
5482446 Williamson et al. Jan 1996 A
5485408 Blomquist Jan 1996 A
5551850 Williamson et al. Sep 1996 A
5558638 Evers et al. Sep 1996 A
5569186 Lord et al. Oct 1996 A
5658250 Blomquist et al. Aug 1997 A
5658252 Johnson Aug 1997 A
5665065 Colman et al. Sep 1997 A
5669877 Blomquist Sep 1997 A
5681285 Ford et al. Oct 1997 A
5685844 Marttila Nov 1997 A
5695473 Olsen Dec 1997 A
5713856 Eggers et al. Feb 1998 A
5782805 Meinzer Jul 1998 A
5810771 Blomquist Sep 1998 A
5822715 Worthington et al. Oct 1998 A
5876370 Blomquist Mar 1999 A
5879143 Cote Mar 1999 A
5935099 Peterson et al. Aug 1999 A
5935106 Olsen Aug 1999 A
5960403 Brown Sep 1999 A
6024539 Blomquist Feb 2000 A
6077055 Vilks Jun 2000 A
6175752 Say et al. Jan 2001 B1
6241704 Peterson et al. Jun 2001 B1
6248057 Mavity et al. Jun 2001 B1
6422057 Anderson Jul 2002 B1
6475180 Peterson et al. Nov 2002 B2
6505059 Kollias et al. Jan 2003 B1
6535714 Melker et al. Mar 2003 B2
6544229 Danby et al. Apr 2003 B1
6551276 Mann et al. Apr 2003 B1
6553244 Lesho et al. Apr 2003 B2
6554798 Mann et al. Apr 2003 B1
6558320 Causey, III et al. May 2003 B1
6558351 Steil et al. May 2003 B1
6565509 James et al. May 2003 B1
6641533 Causey, III et al. Nov 2003 B2
6744350 Blomquist Jun 2004 B2
6773412 O'Mahony Aug 2004 B2
6809653 Mann et al. Oct 2004 B1
6827702 Lebel et al. Dec 2004 B2
6852104 Blomquist Feb 2005 B2
6862466 Ackerman Mar 2005 B2
6872200 Mann et al. Mar 2005 B2
6882940 Potts et al. Apr 2005 B2
6918542 Silverbrook et al. Jul 2005 B2
6936029 Mann et al. Aug 2005 B2
6979326 Mann et al. Dec 2005 B2
6997920 Mann et al. Feb 2006 B2
7022072 Fox et al. Apr 2006 B2
7025743 Mann et al. Apr 2006 B2
7033338 Vilks Apr 2006 B2
7041082 Blomquist et al. May 2006 B2
7073713 Silverbrook et al. Jul 2006 B2
7083108 Silverbrook et al. Aug 2006 B2
7092011 Silverbrook et al. Aug 2006 B2
7097104 Silverbrook et al. Aug 2006 B2
7098803 Mann et al. Aug 2006 B2
7109878 Mann et al. Sep 2006 B2
7156808 Quy Jan 2007 B2
7179226 Crothall et al. Feb 2007 B2
7187404 Silverbrook et al. Mar 2007 B2
7201319 Silverbrook et al. Apr 2007 B2
7231263 Choi Jun 2007 B2
7234645 Silverbrook et al. Jun 2007 B2
7254782 Sherer Aug 2007 B1
7267665 Steil et al. Sep 2007 B2
7278983 Ireland et al. Oct 2007 B2
7289142 Silverbrook Oct 2007 B2
7291107 Hellwig et al. Nov 2007 B2
7307245 Faries et al. Dec 2007 B2
7320675 Pastore et al. Jan 2008 B2
7324012 Mann et al. Jan 2008 B2
7347836 Peterson et al. Mar 2008 B2
7362971 Silverbrook et al. Apr 2008 B2
7373083 Silverbrook et al. May 2008 B2
7377706 Silverbrook et al. May 2008 B2
7399277 Saidara et al. Jul 2008 B2
7404796 Ginsberg Jul 2008 B2
7460152 Silverbrook et al. Dec 2008 B2
7464010 Yang et al. Dec 2008 B2
7471994 Ford et al. Dec 2008 B2
7475825 Silverbrook et al. Jan 2009 B2
7483050 Silverbrook et al. Jan 2009 B2
7515060 Blomquist Apr 2009 B2
7524045 Silverbrook et al. Apr 2009 B2
7534226 Mernoe et al. May 2009 B2
7547281 Hayes et al. Jun 2009 B2
7553281 Hellwig et al. Jun 2009 B2
7569030 Lebel et al. Aug 2009 B2
7602310 Mann et al. Oct 2009 B2
7654976 Peterson et al. Feb 2010 B2
7676519 Mcbride et al. Mar 2010 B2
7697967 Stafford Apr 2010 B2
7708717 Estes et al. May 2010 B2
7717903 Estes et al. May 2010 B2
7722536 Goodnow May 2010 B2
7734323 Blomquist Jun 2010 B2
7751907 Blomquist Jul 2010 B2
7766829 Sloan et al. Aug 2010 B2
7766830 Fox et al. Aug 2010 B2
7776030 Estes et al. Aug 2010 B2
7778680 Goode, Jr. et al. Aug 2010 B2
7794426 Briones et al. Sep 2010 B2
7794427 Estes et al. Sep 2010 B2
7794428 Estes et al. Sep 2010 B2
7797028 Goode, Jr. et al. Sep 2010 B2
7806886 Kanderian et al. Oct 2010 B2
7828528 Estes et al. Nov 2010 B2
7833196 Estes et al. Nov 2010 B2
7837651 Bishop et al. Nov 2010 B2
7850641 Lebel et al. Dec 2010 B2
7860544 Say et al. Dec 2010 B2
7869851 Hellwig et al. Jan 2011 B2
7869853 Say et al. Jan 2011 B1
7885699 Say et al. Feb 2011 B2
7887512 Estes et al. Feb 2011 B2
7892199 Mhatre et al. Feb 2011 B2
7912674 Killoren Clark et al. Mar 2011 B2
7914450 Goode, Jr. et al. Mar 2011 B2
7933780 De La Huerga Apr 2011 B2
7935076 Estes et al. May 2011 B2
7938797 Estes May 2011 B2
7938803 Mernoe et al. May 2011 B2
7959598 Estes Jun 2011 B2
7981034 Jennewine et al. Jul 2011 B2
7981084 Estes et al. Jul 2011 B2
7981102 Patel et al. Jul 2011 B2
7983745 Hatlestad et al. Jul 2011 B2
7983759 Stahmann et al. Jul 2011 B2
7988630 Osorio et al. Aug 2011 B1
7988849 Biewer et al. Aug 2011 B2
7996158 Hayter et al. Aug 2011 B2
8016783 Pastore et al. Sep 2011 B2
8025634 Moubayed et al. Sep 2011 B1
8105268 Lebel et al. Jan 2012 B2
8105279 Mernoe et al. Jan 2012 B2
8109921 Estes et al. Feb 2012 B2
8177716 Say et al. May 2012 B2
8182445 Moubayed et al. May 2012 B2
8192394 Estes et al. Jun 2012 B2
8204729 Sher Jun 2012 B2
8206296 Jennewine Jun 2012 B2
8208984 Blomquist Jun 2012 B2
8211062 Estes et al. Jul 2012 B2
8219222 Blomquist Jul 2012 B2
8221345 Blomquist Jul 2012 B2
8221385 Estes Jul 2012 B2
8226558 Say et al. Jul 2012 B2
8246540 Ginsberg Aug 2012 B2
8260630 Brown Sep 2012 B2
8277435 Estes Oct 2012 B2
8282601 Mernoe et al. Oct 2012 B2
8287454 Wolpert et al. Oct 2012 B2
8287495 Michaud et al. Oct 2012 B2
8290562 Goode, Jr. et al. Oct 2012 B2
8323188 Tran Dec 2012 B2
8328754 Estes et al. Dec 2012 B2
8344847 Moberg et al. Jan 2013 B2
8357091 Say et al. Jan 2013 B2
8376943 Kovach et al. Feb 2013 B2
8380273 Say et al. Feb 2013 B2
8409131 Say et al. Apr 2013 B2
8454575 Estes et al. Jun 2013 B2
8486005 Yodfat et al. Jul 2013 B2
8579853 Reggiardo et al. Nov 2013 B2
8657779 Blomquist Feb 2014 B2
8712748 Thukral et al. Apr 2014 B2
8882701 DeBelser et al. Nov 2014 B2
9008803 Blomquist Apr 2015 B2
20010031944 Peterson et al. Oct 2001 A1
20010037217 Abensour et al. Nov 2001 A1
20020072932 Swamy Jun 2002 A1
20020077852 Ford et al. Jun 2002 A1
20020143580 Bristol et al. Oct 2002 A1
20020183693 Peterson et al. Dec 2002 A1
20030032867 Crothall et al. Feb 2003 A1
20030050621 Lebel et al. Mar 2003 A1
20030060765 Campbell et al. Mar 2003 A1
20030114836 Estes et al. Jun 2003 A1
20030160683 Blomquist Aug 2003 A1
20030163088 Blomquist Aug 2003 A1
20030163090 Blomquist et al. Aug 2003 A1
20030208113 Mault et al. Nov 2003 A1
20030212364 Mann et al. Nov 2003 A1
20030212379 Bylund et al. Nov 2003 A1
20040054263 Moerman et al. Mar 2004 A1
20040073095 Causey, III et al. Apr 2004 A1
20040115067 Rush et al. Jun 2004 A1
20040180810 Pilarski Sep 2004 A1
20040193025 Steil et al. Sep 2004 A1
20040225252 Gillespie, Jr. et al. Nov 2004 A1
20040254434 Goodnow et al. Dec 2004 A1
20050022274 Campbell et al. Jan 2005 A1
20050027182 Siddiqui et al. Feb 2005 A1
20050030164 Blomquist Feb 2005 A1
20050050621 Thomas Mar 2005 A1
20050065760 Murtfeldt et al. Mar 2005 A1
20050137530 Campbell et al. Jun 2005 A1
20050143864 Blomquist Jun 2005 A1
20050171513 Mann et al. Aug 2005 A1
20050197553 Cooper Sep 2005 A1
20050197621 Poulsen et al. Sep 2005 A1
20050272640 Doyle et al. Dec 2005 A1
20050277872 Colby et al. Dec 2005 A1
20060001550 Mann et al. Jan 2006 A1
20060031094 Cohen et al. Feb 2006 A1
20060047192 Hellwig et al. Mar 2006 A1
20060047538 Condurso et al. Mar 2006 A1
20060080059 Stupp et al. Apr 2006 A1
20060085223 Anderson Apr 2006 A1
20060093785 Hickle May 2006 A1
20060132292 Blomquist Jun 2006 A1
20060167345 Vespasiani Jul 2006 A1
20060202859 Mastrototaro et al. Sep 2006 A1
20060253097 Braig et al. Nov 2006 A1
20060253296 Liisberg et al. Nov 2006 A1
20060276771 Galley et al. Dec 2006 A1
20070016449 Cohen et al. Jan 2007 A1
20070033074 Nitzan et al. Feb 2007 A1
20070060796 Kim Mar 2007 A1
20070060871 Istoc et al. Mar 2007 A1
20070060874 Nesbitt et al. Mar 2007 A1
20070073236 Mernoe et al. Mar 2007 A1
20070083152 Williams, Jr. Apr 2007 A1
20070093786 Goldsmith et al. Apr 2007 A1
20070100222 Mastrototaro et al. May 2007 A1
20070112298 Mueller, Jr. et al. May 2007 A1
20070118405 Campbell et al. May 2007 A1
20070124002 Estes et al. May 2007 A1
20070149861 Crothall et al. Jun 2007 A1
20070156033 Causey, III et al. Jul 2007 A1
20070156092 Estes et al. Jul 2007 A1
20070167905 Estes et al. Jul 2007 A1
20070167912 Causey et al. Jul 2007 A1
20070173762 Estes et al. Jul 2007 A1
20070179355 Rosen Aug 2007 A1
20070179444 Causey et al. Aug 2007 A1
20070213657 Jennewine et al. Sep 2007 A1
20070245258 Ginggen et al. Oct 2007 A1
20070255348 Holtzclaw Nov 2007 A1
20070287985 Estes Dec 2007 A1
20080030369 Mann et al. Feb 2008 A1
20080033357 Mann et al. Feb 2008 A1
20080033360 Evans et al. Feb 2008 A1
20080045902 Estes et al. Feb 2008 A1
20080045903 Estes et al. Feb 2008 A1
20080045904 Estes et al. Feb 2008 A1
20080045931 Estes et al. Feb 2008 A1
20080065007 Peterson Mar 2008 A1
20080065016 Peterson Mar 2008 A1
20080071209 Moubayed Mar 2008 A1
20080071210 Moubayed et al. Mar 2008 A1
20080071217 Moubayed Mar 2008 A1
20080071251 Moubayed Mar 2008 A1
20080071580 Marcus et al. Mar 2008 A1
20080097289 Steil et al. Apr 2008 A1
20080106431 Blomquist May 2008 A1
20080114299 Damgaard-Sorensen et al. May 2008 A1
20080132844 Peterson Jun 2008 A1
20080139907 Rao et al. Jun 2008 A1
20080147004 Mann et al. Jun 2008 A1
20080171967 Blomquist et al. Jul 2008 A1
20080172026 Blomquist Jul 2008 A1
20080172027 Blomquist Jul 2008 A1
20080172028 Blomquist Jul 2008 A1
20080172029 Blomquist Jul 2008 A1
20080172030 Blomquist Jul 2008 A1
20080172031 Blomquist Jul 2008 A1
20080177165 Blomquist Jul 2008 A1
20080206799 Blomquist Aug 2008 A1
20080228056 Blomquist et al. Sep 2008 A1
20080269585 Ginsberg Oct 2008 A1
20080287922 Panduro Nov 2008 A1
20080288115 Rusnak et al. Nov 2008 A1
20080294024 Cosentino et al. Nov 2008 A1
20080294094 Mhatre et al. Nov 2008 A1
20080294108 Briones et al. Nov 2008 A1
20080294109 Estes et al. Nov 2008 A1
20080294142 Patel Nov 2008 A1
20080294294 Blomquist Nov 2008 A1
20080300534 Blomquist Dec 2008 A1
20080300572 Rankers et al. Dec 2008 A1
20080300651 Gerber et al. Dec 2008 A1
20080306434 Dobbles et al. Dec 2008 A1
20080306444 Brister et al. Dec 2008 A1
20090018779 Cohen et al. Jan 2009 A1
20090030733 Cohen et al. Jan 2009 A1
20090067989 Estes et al. Mar 2009 A1
20090069745 Estes et al. Mar 2009 A1
20090069787 Estes et al. Mar 2009 A1
20090085768 Patel et al. Apr 2009 A1
20090093756 Minaie Apr 2009 A1
20090112626 Talbot et al. Apr 2009 A1
20090143661 Taub et al. Jun 2009 A1
20090150186 Cohen et al. Jun 2009 A1
20090150865 Young et al. Jun 2009 A1
20090163855 Shin et al. Jun 2009 A1
20090171269 Jennewine et al. Jul 2009 A1
20090177147 Blomquist et al. Jul 2009 A1
20090212966 Panduro Aug 2009 A1
20090240193 Mensinger et al. Sep 2009 A1
20090247931 Damgaard-Sorensen Oct 2009 A1
20090267774 Enegren et al. Oct 2009 A1
20090267775 Enegren et al. Oct 2009 A1
20090270705 Enegren et al. Oct 2009 A1
20090270810 Debelser et al. Oct 2009 A1
20090275887 Estes Nov 2009 A1
20090281393 Smith Nov 2009 A1
20100010330 Rankers et al. Jan 2010 A1
20100049164 Estes Feb 2010 A1
20100056993 Chase Mar 2010 A1
20100094251 Estes Apr 2010 A1
20100174266 Estes Jul 2010 A1
20100174553 Kaufman et al. Jul 2010 A1
20100192686 Kamen et al. Aug 2010 A1
20100198034 Thomas et al. Aug 2010 A1
20100205001 Knudsen et al. Aug 2010 A1
20100218132 Soni et al. Aug 2010 A1
20100222765 Blomquist Sep 2010 A1
20100228186 Estes et al. Sep 2010 A1
20100234709 Say et al. Sep 2010 A1
20100235439 Goodnow Sep 2010 A1
20100261987 Kamath et al. Oct 2010 A1
20100262434 Shaya Oct 2010 A1
20100274592 Nitzan et al. Oct 2010 A1
20100274751 Blomquist Oct 2010 A1
20100277119 Montague et al. Nov 2010 A1
20100286563 Bryer et al. Nov 2010 A1
20100298681 Say et al. Nov 2010 A1
20100305965 Benjamin et al. Dec 2010 A1
20100324382 Cantwell et al. Dec 2010 A1
20110006876 Moberg et al. Jan 2011 A1
20110009725 Hill et al. Jan 2011 A1
20110009813 Rankers Jan 2011 A1
20110022025 Savoie et al. Jan 2011 A1
20110033833 Blomquist et al. Feb 2011 A1
20110050428 Istoc Mar 2011 A1
20110053121 Heaton Mar 2011 A1
20110071465 Wang et al. Mar 2011 A1
20110077481 Say et al. Mar 2011 A1
20110077963 Knudsen et al. Mar 2011 A1
20110092894 Mcgill et al. Apr 2011 A1
20110105955 Yudovsky et al. May 2011 A1
20110112504 Causey et al. May 2011 A1
20110118578 Timmerman May 2011 A1
20110118662 Mhatre et al. May 2011 A1
20110124996 Reinke et al. May 2011 A1
20110125085 Mcgill et al. May 2011 A1
20110126188 Bernstein et al. May 2011 A1
20110133946 Kopp et al. Jun 2011 A1
20110137239 DeBelser Jun 2011 A1
20110172744 Davis et al. Jul 2011 A1
20110213225 Bernstein et al. Sep 2011 A1
20110256024 Cole et al. Oct 2011 A1
20120030610 DiPerna et al. Feb 2012 A1
20120059673 Cohen et al. Mar 2012 A1
20120226124 Blomquist Sep 2012 A1
20120232484 Blomquist Sep 2012 A1
20120232485 Blomquist Sep 2012 A1
20120232520 Sloan et al. Sep 2012 A1
20120232521 Blomquist Sep 2012 A1
20120245524 Estes et al. Sep 2012 A1
20120265722 Blomquist Oct 2012 A1
20140012511 Mensinger et al. Jan 2014 A1
20150045770 DeBelser et al. Feb 2015 A1
Foreign Referenced Citations (19)
Number Date Country
1571582 Sep 2005 EP
200634323 Feb 2006 JP
WO0045696 Aug 2000 WO
WO0152727 Jul 2001 WO
WO02062212 Aug 2002 WO
WO2005046559 May 2005 WO
WO2007000425 Jan 2007 WO
WO2007056592 May 2007 WO
WO2008091320 Jul 2008 WO
WO2008103175 Aug 2008 WO
WO2008144693 Nov 2008 WO
WO2008144695 Nov 2008 WO
WO2008144697 Nov 2008 WO
WO2008144698 Nov 2008 WO
WO2008153689 Dec 2008 WO
WO2008153819 Dec 2008 WO
WO2009032399 Mar 2009 WO
WO2009032400 Mar 2009 WO
WO2009035759 Mar 2009 WO
Non-Patent Literature Citations (24)
Entry
IPRP and Written Opinion for International Application No. PCT/US2010/056226 dated Jun. 14, 2012.
Canadian Office Action for Canadian Application No. 2,782,673 dated Sep. 10, 2013,.
International Search Report and Written Opinion for International Application No. PCT/US2007/024424 dated Mar. 6, 2009.
European Office Action for European Application No. 08779626.4 dated May 25, 2010.
Deltec Cozmo, Personalized Insulin Pump. Starting Guide, Smith Medical MD, Inc. online. http://web.archive.org/web/20041207133223/http://www. cozmore.com/Library/upload/starting—guide—032004.pdf., Dec. 7, 2004. pp. 1-83.
International Search Report and Written Opinion for International Application No. PCT/US2008/006449 dated Oct. 10, 2008.
International Search Report and Written Opinion for International Application No. PCT/US2008/006801 dated Oct. 30, 2008.
Wikipedia define “basal rate” printed on Jun. 12, 2009.
Compare Insulin Pump for Diabetes, www.diabetesnet.com printed on Jun. 18, 2009.
Walsh, et al., “Title Page, Citiation page and table of contents” Pumping Insulin: Everything You need for Success on a Smart Insulin Pump. Torrey Pines Press, San Diego 2006.
European Office Action for European Application No. 08767734.6 dated Apr. 7, 2010. 6 pages.
Walsh et al., Select and Test Your Correction Factor Pumping Insulin Fourth Edition, Chapter 13. (2006) 29 pages.
Application and File History for U.S. Appl. No. 11/626,653, filed Jan. 24, 2007, inventors Blomquist et al.
Application and File History for U.S. Appl. No. 12/720,306, filed Mar. 9, 2010, inventors Blomquist et al.
Application and File History for U.S. Appl. No. 11/755,480, filed May 30, 2007, inventor Blomquist.
Application and File History for U.S. Appl. No. 13/465,570, filed May 7, 2012, inventor Blomquist.
Japanese Office Action for Japanese Application No. 2012542037 dated Sep. 2, 2014. English translation not provided.
Chinese Office Action for Chinese Application No. 201080063326.9 dated Jan. 27, 2014. English Translation not provided.
Application and File History for U.S. Appl. No. 12/631,076, filed Dec. 4, 2009, inventors DeBelser et al.
Application and File History for U.S. Appl. No. 14/525,579, filed Oct. 28, 2014, inventors DeBelser et al.
Application and File History for U.S. Appl. No. 14/187,414, filed Feb. 24, 2014, inventor Blomquist.
Application and File History for U.S. Appl. No. 11/753,420, filed May 24, 2007, inventor Blomquist.
Application and File History for U.S. Appl. No. 12/774,991, filed May 6, 2010, inventor Blomquist.
Application and File History for U.S. Appl. No. 13/530,404, filed Jun. 22, 2012, inventor Blomquist.
Related Publications (1)
Number Date Country
20150217044 A1 Aug 2015 US
Continuations (3)
Number Date Country
Parent 13530404 Jun 2012 US
Child 14684495 US
Parent 12774991 May 2010 US
Child 13530404 US
Parent 11753420 May 2007 US
Child 12774991 US